The role of inflammation in progression of breast cancer: Friend or foe? (Review)
- Authors:
- Michael D. Allen
- Louise J. Jones
-
Affiliations: Centre for Tumour Biology, Barts Cancer Institute, A Cancer Research UK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, London EC1M 6BQ, UK - Published online on: July 8, 2015 https://doi.org/10.3892/ijo.2015.3075
- Pages: 797-805
This article is mentioned in:
Abstract
 |
|
Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, et al: Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 102:627–637. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Price P, Sinnett HD, Gusterson B, Walsh G, A'Hern RP and McKinna JA: Duct carcinoma in situ: Predictors of local recurrence and progression in patients treated by surgery alone. Br J Cancer. 61:869–872. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Welch HG and Black WC: Overdiagnosis in cancer. J Natl Cancer Inst. 102:605–613. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, et al: Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA. 100:5974–5979. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Castro NP, Osório CA, Torres C, Bastos EP, Mourão-Neto M, Soares FA, Brentani HP and Carraro DM: Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res. 10:R872008. View Article : Google Scholar : PubMed/NCBI | |
|
Moelans CB, de Weger RA, Monsuur HN, Maes AH and van Diest PJ: Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: A multiplex ligation-dependent probe amplification study. Anal Cell Pathol (Amst). 33:165–173. 2010. View Article : Google Scholar | |
|
Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW Jr, et al: A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 105:701–710. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Allen M and Jones LJ: Jekyll and Hyde: The role of the micro-environment on the progression of cancer. J Pathol. 223:162–176. 2011. View Article : Google Scholar | |
|
Bissell MJ, Hall HG and Parry G: How does the extracellular matrix direct gene expression? J Theor Biol. 99:31–68. 1982. View Article : Google Scholar : PubMed/NCBI | |
|
Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E and Syrjänen K: Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer. 28A:859–864. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Stewart T, Tsai SC, Grayson H, Henderson R and Opelz G: Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet. 346:796–798. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Lee AH, Happerfield LC, Bobrow LG and Millis RR: Angiogenesis and inflammation in ductal carcinoma in situ of the breast. J Pathol. 181:200–206. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN and Pollard JW: Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 66:11238–11246. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lee AH, Dublin EA and Bobrow LG: Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast. J Pathol. 187:285–290. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J and Harris AL: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56:4625–4629. 1996.PubMed/NCBI | |
|
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, et al: The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann Oncol. 26:259–271. 2015. View Article : Google Scholar | |
|
Biswas SK and Mantovani A: Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunol. 11:889–896. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tang X: Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett. 332:3–10. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bögels M, Braster R, Nijland PG, Gül N, van de Luijtgaarden W, Fijneman RJ, Meijer GA, Jimenez CR, Beelen RH and van Egmond M: Carcinoma origin dictates differential skewing of monocyte function. OncoImmunology. 1:798–809. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC and Balkwill FR: ‘Re-educating' tumor-associated macrophages by targeting NF-kappaB. J Exp Med. 205:1261–1268. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Coussens LM and Pollard JW: Leukocytes in mammary development and cancer. Cold Spring Harb Perspect Biol. 3:32011. View Article : Google Scholar | |
|
Guy CT, Cardiff RD and Muller WJ: Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol. 12:954–961. 1992.PubMed/NCBI | |
|
Scholl SM, Pallud C, Beuvon F, Hacene K, Stanley ER, Rohrschneider L, Tang R, Pouillart P and Lidereau R: Anticolony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst. 86:120–126. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Lin EY, Nguyen AV, Russell RG and Pollard JW: Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 193:727–740. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al: Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1:54–67. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Soria G and Ben-Baruch A: The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 267:271–285. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Murdoch C, Giannoudis A and Lewis CE: Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood. 104:2224–2234. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, Roques S and Lazennec G: Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res. 9:R152007. View Article : Google Scholar : PubMed/NCBI | |
|
Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H and Matsushima K: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 6:3282–3289. 2000.PubMed/NCBI | |
|
Goede V, Brogelli L, Ziche M and Augustin HG: Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer. 82:765–770. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Valković T, Lucin K, Krstulja M, Dobi-Babić R and Jonjić N: Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract. 194:335–340. 1998. View Article : Google Scholar | |
|
Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, Barry FP, O'Brien T and Kerin MJ: Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res. 13:5020–5027. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lebrecht A, Grimm C, Lantzsch T, Ludwig E, Hefler L, Ulbrich E and Koelbl H: Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol. 25:14–17. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lyon DE, McCain NL, Walter J and Schubert C: Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res. 57:51–58. 2008. View Article : Google Scholar : | |
|
Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA and Pollard JW: CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 475:222–225. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, Chaitchik S, Keydar I and Ben-Baruch A: Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 59:4681–4687. 1999.PubMed/NCBI | |
|
Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y and Abe A: Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res. 7:285–289. 2001.PubMed/NCBI | |
|
Yaal-Hahoshen N, Shina S, Leider-Trejo L, Barnea I, Shabtai EL, Azenshtein E, Greenberg I, Keydar I and Ben-Baruch A: The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res. 12:4474–4480. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Stormes KA, Lemken CA, Lepre JV, Marinucci MN and Kurt RA: Inhibition of metastasis by inhibition of tumor-derived CCL5. Breast Cancer Res Treat. 89:209–212. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE and Balkwill FR: A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res. 63:8360–8365. 2003.PubMed/NCBI | |
|
Velasco-Velázquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP and Pestell RG: CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 72:3839–3850. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R and Weinberg RA: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 449:557–563. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, et al: A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood. 107:2112–2122. 2006. View Article : Google Scholar | |
|
Jubb AM, Soilleux EJ, Turley H, Steers G, Parker A, Low I, Blades J, Li JL, Allen P, Leek R, et al: Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am J Pathol. 176:2019–2028. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H and Era S: Macrophage infiltration and its prognostic implications in breast cancer: The relationship with VEGF expression and microvessel density. Oncol Rep. 14:425–431. 2005.PubMed/NCBI | |
|
Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO and Green AR: Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol. 65:159–163. 2012. View Article : Google Scholar | |
|
Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, et al: Expression of interleukin-1beta in human breast carcinoma. Cancer. 80:421–434. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Slaney CY, Rautela J and Parker BS: The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. Cancer Res. 73:5852–5857. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, et al: Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 18:1224–1231. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, et al: Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell. 13:23–35. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Melani C, Sangaletti S, Barazzetta FM, Werb Z and Colombo MP: Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 67:11438–11446. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Lv D, Kim HJ, Kurt RA, Bu W, Li Y and Ma X: A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells. Cell Res. 23:394–408. 2013. View Article : Google Scholar : | |
|
Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ and Montero AJ: Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 58:49–59. 2009. View Article : Google Scholar | |
|
Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J and Ren X: Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 190:3783–3797. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chin Y, Janseens J, Vandepitte J, Vandenbrande J, Opdebeek L and Raus J: Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res. 12:1463–1466. 1992.PubMed/NCBI | |
|
Watanabe MA, Oda JM, Amarante MK and Cesar Voltarelli J: Regulatory T cells and breast cancer: Implications for immuno-pathogenesis. Cancer Metastasis Rev. 29:569–579. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S and Lee PP: Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med. 2:e2842005. View Article : Google Scholar : PubMed/NCBI | |
|
Fontenot JD, Gavin MA and Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 4:330–336. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Bacchetta R, Passerini L, Gambineri E, Dai M, Allan SE, Perroni L, Dagna-Bricarelli F, Sartirana C, Matthes-Martin S, Lawitschka A, et al: Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest. 116:1713–1722. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, Ocheltree EL, Greenberg PD, Ochs HD and Rudensky AY: Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA. 103:6659–6664. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Li B, Saouaf SJ, Samanta A, Shen Y, Hancock WW and Greene MI: Biochemistry and therapeutic implications of mechanisms involved in FOXP3 activity in immune suppression. Curr Opin Immunol. 19:583–588. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Gupta S, Joshi K, Wig JD and Arora SK: Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis. Acta Oncol. 46:792–797. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL and Banham AH: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 24:5373–5380. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y and Zheng P: FOXP3 and breast cancer: Implications for therapy and diagnosis. Pharmacogenomics. 8:1485–1487. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO and Green AR: Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 29:1949–1955. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wernicke M: Quantitative morphologic assessment of immuno-reactivity in regional lymph nodes of patients with carcinoma of the breast. Surg Gynecol Obstet. 140:919–924. 1975.PubMed/NCBI | |
|
Urdiales-Viedma M, Nogales-Fernandez F, Martos-Padilla S and Sanchez-Cantalejo E: Breast tumors: Immunoglobulins in axillary lymph nodes. Tumori. 72:575–579. 1986.PubMed/NCBI | |
|
Tan EM and Shi FD: Relative paradigms between autoantibodies in lupus and autoantibodies in cancer. Clin Exp Immunol. 134:169–177. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO and Green AR: The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 132:545–553. 2012. View Article : Google Scholar | |
|
Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kölbl H and Gehrmann M: The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 68:5405–5413. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N and Coussens LM: CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 16:91–102. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
van der Most RG, Currie AJ, Robinson BW and Lake RA: Decoding dangerous death: How cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. Cell Death Differ. 15:13–20. 2008. View Article : Google Scholar | |
|
Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A and Kroemer G: The anticancer immune response: Indispensable for therapeutic success? J Clin Invest. 118:1991–2001. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L and Smyth MJ: Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 71:4809–4820. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Criscitiello C and Curigliano G: Immunotherapeutics for breast cancer. Curr Opin Oncol. 25:602–608. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, et al: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 26:1789–1796. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et al: Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 32:2959–2966. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 31:860–867. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, et al: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol. 25:1544–1550. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, et al: Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol. 33:701–708. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T and Dermime S: FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 8:572008. View Article : Google Scholar | |
|
Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D and Gillanders WE: The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 139:667–676. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 515:558–562. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al: Improved survival with ipilimumab in patients with meta-static melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 364:2517–2526. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Vonderheide RH, LoRusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D, Dorazio P, Trosko JA, Rüter J, Mariani GL, et al: Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res. 16:3485–3494. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW and Smyth MJ: Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA. 108:7142–7147. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hünig T: The storm has cleared: Lessons from the CD28 super-agonist TGN1412 trial. Nat Rev Immunol. 12:317–318. 2012. View Article : Google Scholar |
